30th Jun 2008 17:20
Not for release, publication or distribution directly or indirectly in or into the United States, Canada, Australia or Japan
AstraZeneca launches and prices a EUR 500 million eurobond
AstraZeneca PLC, rated A1 (stable) by Moody's and AA- (stable) by Standard & Poor's, announces the successful pricing of a EUR 500 million eurobond transaction (the "Bond"). The proceeds of the issue will be used to repay a portion of the outstanding US commercial paper taken on in connection with the acquisition of MedImmune.
The bond is a EUR 500 million, fixed rate issue with a coupon of 5.625 per cent maturing 4th January 2010 and was issued under AstraZeneca PLC's Euro Medium Term Note (EMTN) programme.
The Bonds will be issued to institutional investors outside the US in accordance with Regulation S of the U.S. Securities Act of 1933, as amended. The Bonds will be admitted to listing on the UKLA's Official List and to trading on the regulated market of the London Stock Exchange.
30 June 2008
Media Enquiries:
Steve Brown +44 207 304 5033 (24 hours)
Chris Sampson +44 20 7304 5130 (24 hours)
Neil McCrae +44 207 304 5045 (24 hours)
Investor Enquiries UK:
Jonathan Hunt +44 207 304 5087 mob: +44 7775 704032
Mina Blair +44 20 7304 5084 mob: +44 7718 581021
Karl Hard +44 207 304 5322 mob: +44 7789 654364
Investor Enquiries US:
Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043
Peter Vozzo (MedImmune) +1 301 398 4358 mob: +1 301 252 7518
About AstraZeneca
AstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more Information visit www.astrazeneca.com
About the announcement
This announcement is for information only and does not constitute an offer or invitation to subscribe for or purchase any securities.
The securities have not been, nor will they be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and no securities shall be offered or sold in the United States or to U.S. persons (as those terms are defined in Regulation S under the Securities Act) absent registration or an applicable exemption from the registration requirements of the Securities Act. There will be no public offering of the securities in the United States in connection with this transaction.
- Ends -
Related Shares:
Astrazeneca